Wyss Institute at Harvard University的动态

CBC Group's R-Bridge Healthcare Fund has announced?$40 million?structured financing transaction with Mirxes, a?Singapore-based miRNA technology company specialising in cancer early detection and precision medicine.? #startups #funding #diagnsotics #precisionmedicine #clinicaltrial #financingsolutions https://lnkd.in/gzP3HiNT

? Calling all entrepreneurs: what do you see as the greatest challenge in oncology business development? ? I’ll be a speaker during this Johnson & Johnson Innovation – JLABS program and will share my expertise in investments, partnering and collaborations in oncology. I hope these insights will support startups in tackling their most daunting challenges. ? Innovators can register here: https://lnkd.in/eGV_hQ4a ? #Biotech #startups #oncology #jnjinnovation

CURO BIOSCIENCES PRIVATE LIMITED, under its brand ErlySign, has secured ?16 crore in pre-Series A funding from renowned investor Ashish Kacholia, facilitated by DerivativeSaint. This milestone sets the stage for a breakthrough in cancer diagnostics, offering hope to millions worldwide. ErlySign is transforming cancer detection with a saliva-based test kit capable of identifying oral precancerous conditions in just 15 minutes. Non-invasive, affordable, and incredibly accurate (100% specificity, 98.04% sensitivity), this innovation eliminates the need for painful biopsies and complex imaging procedures. As Shubhendra Singh Thakur, CEO and Founder of ErlySign, stated: “Our innovation goes beyond early detection. It’s about reshaping healthcare by making diagnostics accessible, affordable, and accurate for all.” ErlySign’s journey is a testament to the power of innovation in healthcare. With the diagnostics market projected to reach $250 billion by 2030, this advancement couldn’t come at a more crucial time. ???????? ?????? ???????? ?????????? ????????: https://lnkd.in/dmt2aUzG Deovrat Begde #earlysign #fundingnews #startupindia #cancerawareness #Earlycancerdetection #indianstartups #vcfunding #startupfunding #funding #startupnews

?? Seattle's Talus Bio Secures $11.2M to Tackle 'Undruggable' Disease Targets! ???? Exciting news from the biotech frontier! Talus Bioscience, a Seattle-based startup, has raised $11.2M in venture capital to push the boundaries of drug discovery for hard-to-treat diseases. Founded by Alex Federation and Lindsay Pino in 2020, Talus is leveraging its innovative MARMOT platform to target gene-regulating proteins often deemed "undruggable." ?? With this new funding, Talus will advance its programs, including a focus on Brachyury—a transcription factor linked to a rare bone cancer—and another related to prostate cancer. Backed by top-tier investors like Two Bear Capital and WRF Capital, Talus is poised to make a significant impact on the future of disease treatment. ???? #Biotech #Startup #DrugDiscovery #UndruggableTargets #SeattleInnovation #Proteomics #CancerResearch #VentureCapital #HealthcareInnovation #LinkedInNews

?? #FundingAlert — UAE-based biotech startup BioSapien has raised $5.5M (20.2M AED) in a pre-Series A round led by Global Ventures, with participation from Dara Holdings. Founded in 2018 by Khatija A., BioSapien’s patented MediChip? platform is a 3D-printed, slow-release drug delivery solution designed to treat cancer locally, minimizing systemic side effects and improving patient outcomes. The funding will support clinical trials in Abu Dhabi (starting Q2 2025), enhance product development, scale manufacturing, and onboard new talent. For more information, check out the news: ?? https://lnkd.in/gGDDfMHm ━━━━━━━━━━━━━━━━ #FundingNews #BioSapien #MediChip #CancerTreatment #HealthcareInnovation #GlobalVentures #DrugDelivery #UAE #AbuDhabi #Oncology #ColorectalCancer #USA #Healthtech #biotech

Empowering startups in oncology innovation Calling al entrepreneurs, what do you see as the greatest challenge in oncology business development? ? I’ll be a speaker during this Johnson & Johnson Innovation – JLABS program and will share my experience in company creation, partnering and collaborations in oncology. I hope these insights will support startups in tackling their most daunting challenges. ? Innovators can register here:?https://lnkd.in/d56zRwSy ? #Biotech #startups #oncology #jnjinnovation ?

New Post: Biotech platform General Proximity lands $16m seed - General Proximity, a San Francisco-based biotech platform founded in 2019, has raised $16 million in seed funding led by Aydin Senkut of Felicis, with additional support from Y Combinator, age1, Modi Ventures, and Wilson Sonsini. The funding will expedite the development of treatments targeting undruggable proteins linked to cancer, cardiometabolic diseases, neurodegeneration, and longevity. Senkut expressed confidence in General Proximity's innovative approach to drug discovery, emphasizing its potential to address significant health challenges and enhance human healthspan. Felicis manages over $3 billion in capital, focusing on early-stage investments. Read the full article here https://lnkd.in/dqSAWbEp #Venturecapital #VC #investment #LP #Limited Partner

Cancer-focused biotech startup Immuneel Therapeutics Pvt. Ltd. has raised Rs 100 crore or $12 million in the extension of Series A round from Taiba Middle East FZ LLC. This is the third round of investment for the Bengaluru-based company since its inception in 2018. The company will use these investments for growth and expansion as decided by the board. IMMUNEEL is an innovative biotechnology company that aims to revolutionize cancer treatment in India by providing affordable and accessible solutions. At the forefront of cell, gene, and immunotherapy, they offer hope to millions suffering from this devastating disease. Despite being available in just a few countries, these advanced treatments come with hefty price tags and limited accessibility. IMMUNEEL's mission is to bridge this gap and make life-changing cancer treatments more attainable for all. Since its registration on December 20th, 2018, the company has been working tirelessly towards achieving this goal. ?Kiran Mazumdar Shaw read more at https://lnkd.in/g3ujwAVR #innovation #management #digitalmarketing #technology #creativity #futurism #startups

The founders of UPyTher (member of SBMC) had an exceptional summer: ?? Secured €2.8 Million Grant: In collaboration with SupraPolix BV (another SBMC-member), UPyTher is pushing boundaries to develop a novel therapy for peritoneal cancer, supported by the European Commission (#OPZuid) and Provincie Noord-Brabant. ?? Seed Financing Success: UPyTher has successfully attracted seed funding to advance its lead product, UPT-211, bringing the company closer to clinical trials. ?? Prestigious Award: UPyTher is proud to have received the Anton and Gerard Award, a testament to the team’s hard work and dedication. Co-founder Geert van Almen reflects in this interview on UPyTher’s journey from academia to a startup, emphasizing the importance of agility, partnerships with key opinion leaders (at Catharina Ziekenhuis a.o.) and the invaluable support from investors like BOM (Brabantse Ontwikkelings Maatschappij) Essential Investments BV and #TTT Medtech. ?? Next up? Scaling production methods and preparing for pivotal preclinical studies. UPyTher is just getting started! Read the full article to learn more about UPyTher's journey #Innovation #Healthcare #CancerResearch #Startup #Funding #Biotech #UPyTher #RegmedXB Innovation Origins NL #RegmedXB

ErlySign, previously CURO Biosciences, secured Rs 16 crore in pre-Series A funding led by Ashish Kacholia and advised by DerivativeSaint. The startup, co-founded by Shubhendra Singh Thakur and Deovrat Begde in 2019, showcases a rapid oral cancer detection kit with impressive sensitivity and specificity rates. Aiming for CDSCO approval, ErlySign's innovative saliva-based test offers a non-invasive and cost-effective diagnostic option amidst a growing global diagnostics market. The fresh capital will further R&D, expansion, and patent filings. https://lnkd.in/gzTRem9r #ErlySign #AshishKacholia #oralcancer #detection #funding #fundraise